<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154775</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-C2017003</org_study_id>
    <nct_id>NCT03154775</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of C-CAR011 in B-NHL Patients</brief_title>
  <official_title>Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The study
      will include the following sequential phases: Screening, Pre-Treatment (Cell Product
      Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety(Incidence of adverse events)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission(DOR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Refractory or Relapsed Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CAR011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-CAR011</intervention_name>
    <description>Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>
    <arm_group_label>C-CAR011</arm_group_label>
    <other_name>Anti-CD19 Chimeric Antigen Receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteered to participate in this study and signed informed consent

          2. Age 18-70 years old, male or female

          3. Relapsed or refractory B cell non-Hodgkin's lymphoma

               -  1 Histologically diagnosed as DLBCL(including PMBCL) or follicular lymphoma(grade
                  Ⅲb) according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines
                  (1st edition 2017)

                    1. Progressive disease after the last standard chemotherapy regimens

                    2. Stable disease after the last standard chemotherapy regimens

                    3. Relapsed within 12 months after prior autologous SCT

               -  2 Follicular lymphoma(stage Ⅲ-Ⅳ)(grade Ⅰ-Ⅲa)

                    1. At least 2 prior combination chemotherapy regimens (not including single
                       agent monoclonal antibody (Rituxan) therapy

                    2. Less than 1 year between last chemotherapy and progression

               -  3 Mantle cell lymphoma

                    1. Beyond 1st CR with relapsed or persistent disease and not eligible or
                       appropriate for conventional allogeneic or autologous SCT

                    2. Disease relapsed or progressed after most recent therapy

                    3. Relapsed within 12 months after prior autologous SCT

          4. All subjects must have received adequate prior therapy including anti-CD20 monoclonal
             antibody (unless tumor is CD20-negative) and an anthracycline containing chemotherapy
             regimen. The standardized treatment regimens reference to NCCN non-Hodgkin lymphoma
             Clinical Practice Guidelines (2017 Version 1)

          5. At least one measurable lesion per revised IWG Response Criteria (the longest diameter
             of the tumor ≥ 1.5 cm)

          6. Expected survival ≥ 12 weeks

          7. ECOG score 0-1

          8. Adequate pulmonary, hepatic, renal and cardiac function

          9. At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy
             therapy) prior to leukapheresis,or at least 4 weeks from monoclonal antibody therapy
             prior to CAR T infusion

         10. No contraindications of leukapheresis

         11. Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative, and must agree to take effective contraceptive measures during the trial

        Exclusion Criteria:

          1. Prior treatment with CAR T therapy or any other genetically modified T cell therapy

          2. Relapse after allogeneic hematopoietic stem cell transplantation

          3. Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis
             is allowed), Prophylactic antibiotic, antiviral and antifungal treatment is
             permissible

          4. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as
             acquired, congenital immune deficiency diseases, including but not limited to
             HIV-infected people

          5. Patients with class III and IV heart failure according to the NYHA Heart Failure
             Classifications

          6. QT interval prolongation≥450 ms

          7. A history of epilepsy or other central nervous system disorders

          8. No evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging

          9. The patient had a history of other primary cancers, with the following exceptions

               -  1 Excisional non-melanoma such as cutaneous basal cell carcinoma

               -  2 Cured in situ carcinoma such as cervical cancer, bladder cancer or breast
                  cancer

         10. Subjects with any autoimmune disease or any immune deficiency disease or other disease
             in need of immunosuppressive therapy

         11. Used of systemic steroids within two weeks (using inhaled steroids is an exception)

         12. Women who are pregnant or lactating or have breeding intent in 6 months

         13. Participated in any other clinical trial within three months

         14. The investigators believe that any increase in the risk of the subject or interference
             with the results of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <phone>0086-021-66111019</phone>
    <email>lab7182@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Li, MD,Ph.D.</last_name>
    <phone>0086-021-66111015</phone>
    <email>lilyforever76@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology,Shanghai Tongji Hospital, Tongji University School of Medicin</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aibin Liang, MD,Ph.D.</last_name>
      <phone>0086-021-66111019</phone>
      <email>lab7182@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ping Li, MD,Ph.D.</last_name>
      <phone>0086-021-66111015</phone>
      <email>lilyforever76@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 13, 2017</last_update_submitted>
  <last_update_submitted_qc>May 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

